Products - Head and neck cancers | Topic | NICE

Showing 4 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer [ID6477]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sentinel Node Biopsy approved for pathological staging of clinically T1-T2 N0 oral cancer
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 December 2026